A new trial finds that cetuximab outperforms durvalumab as a second-line treatment in patients who cannot tolerate cisplatin.

TUESDAY, Nov. 26, 2024 (HealthDay News) -- Cisplatin is the go-to chemotherapy for people battling head-and-neck cancers, but ...

Head and neck cancers are the seventh most common type of cancer worldwide, according to the 2020 World Cancer Report.

The monoclonal antibody cetuximab, while not as effective as cisplatin, is often used as an alternative in these patients.

colorectal (colon) cancer; epidermal growth factor receptor (EGFR); RAS; liquid biopsy; rechallenge; cetuximab; RAS; ...

Optimal treatment for patients with locally advanced head and neck squamous cell carcinoma (HNSCC) unfit for cisplatin ...

Explore the challenges and advancements in anti-EGFR antibody treatment for metastatic colorectal cancer. Discover how ...

Several phase II–III studies have shown that the EGFR-targeting monoclonal antibody, cetuximab, offers clinical benefit for patients with SCCHN. Cetuximab monotherapy is active in patients whose ...

The currently approved administration schedule for cetuximab is the weekly schedule (400 mg/m 2 initial dose followed by 250 mg/m 2 weekly); however, the commonly used chemotherapy agents for CRC ...

Indeed, results from the FLEX trial demonstrate that cetuximab in combination with platinum-based chemotherapy is a new treatment strategy for patients with advanced NSCLC. The EGFR pathway has an ...

Cetuximab is a monoclonal antibody with activity against colorectal cancers that overexpress epidermal growth factor receptor. This agent blocks epidermal growth factor receptor signaling and ...

We hope to add results when they are available. One of the targeted drugs they can use is cetuximab. These drugs can help but researchers know that only a small amount of the drugs get into the cancer ...